In this article, featured in the recent Blood Flashback series, Dameshek introduced the concept of myeloproliferative disorders as conditions characterized by excessive proliferation of hematopoietic precursors in the bone marrow and excessive production of mature blood cells. He included in this category chronic granulocytic leukemia, polycythemia vera (PV), idiopathic or agnogenic myeloid metaplasia of spleen, megakaryocytic leukemia, and erythroleukemia. Although some of these names are no longer in use, Dameshek's editorial represents a remarkable example of visionary leadership.
In 2008, to underscore the clonal nature of myeloproliferative disorders, the authors of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues introduced the name "myeloproliferative neoplasms" (MPNs). 2 The revised version of this classification includes the following ; and (4) somatic mutations of CALR in classical MPNs in 2013. 10, 11 The following series of reviews describes the latest advances in our understanding of the genetic basis of MPNs and related myeloid neoplasms, as well as of its clinical relevance: haploinsufficiency, or via complete homozygous loss, and contribute to phenotypic variability, phenotypic shifts, and progression to more aggressive myeloid neoplasms. In the second review, Rumi and I examine the 2016 revision of the World Health Organization (WHO) classification of classical MPNs, and then discuss the need for a deeper integration of clinical features, morphology, immunophenotype, and genetics for defining and managing MPNs. In the third review, Vannucchi and Harrison describe current therapies for ET, PV, and PMF, focusing on emerging aspects within this diverse field. In the fourth review, Reiter and Gotlib examine the myeloid neoplasms with eosinophilia, focusing on the myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2. Finally, Maxson and Tyner discuss the genomics of CNL, a distinct MPN with a high prevalence of mutations in the CSF3R gene. They also examine a related disorder, atypical CML, which has higher genetic complexity, including a high prevalence of somatic mutations in the SETBP1 gene. 12 Collectively, these reviews summarize the last 15 years or so of work in the field of MPNs and related myeloid neoplasms, and provide a perspective for future studies. I hope that Blood readers find this review series of interest.
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